Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment  by BRATEL, T. et al.
Impact of hypoxaemia on neuroendocrine
function and catecholamine secretion in chronic
obstructive pulmonary disease (COPD). Effects
of long-term oxygen treatment
T. BRATEL*, A. WENNLUND{ AND K. CARLSTRO¨M{
Departments of *Respiratory and Allergic Diseases, {Endocrine and Metabolic Diseases and {Obstetrics and
Gynaecology, Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden
The aim of the study was to investigate the effects of chronic hypoxaemia on neuroendocrine function in
hypoxaemic chronic obstructive pulmonary disease (COPD). The stress level was assessed by measurement of
daytime plasma catecholamine and nocturnal urinary catecholamine levels and endocrine function was assessed by
measuring serum gonadotropins, peripheral sex hormones and peripheral thyroid hormones, and by measuring
thyroid stimulating hormone (TSH), prolactin and growth hormone before and after thyroid releasing hormone
challenge in 12 male, stable, hypoxaemic COPD patients before and after at least 4 months of long-term oxygen
treatment (LTOT). Mean pre-treatment PaO2 was 7?39+ 0?78 kPa and mean nocturnal arterial oxygen saturation
(MSaO2) was 86?6+ 3?2%. Plasma norepinephrine (NE) levels were higher than normal, while all other pre-
treatment hormone levels were within normal range. Low forced expiratory volume in 1 sec (FEV1) was associated
with low basal and stimulated TSH (P50?01). Urinary NE excretion correlated positively to nocturnal time spent
with SaO2585% (P50?05). In similarity with normal controls, positive correlations were found between sex
hormone binding globulin and testosterone both before and after LTOT (P50?01). No significant hormonal
changes were noted following an average of 8 months of LTOT for the entire study group. However, in a subgroup
(n=6) with an increase in MSaO2 exceeding 7% points following LTOT, nocturnal excretion of NE and
epinephrine were reduced by 30% (P50?05) and S-free thyroxin by 20% (P50?05).
In conclusion, patients with chronic hypoxaemia secondary to COPD exhibit elevated plasma NE levels but
otherwise normal endocrine levels, including a normal hypothalamic–pituitary–testicular axis. The severity of
airway obstruction is associated with reduced basal and stimulated TSH. The endocrine function is not significantly
changed following LTOT except for a subgroup with severe nocturnal hypoxaemia, where elevated nocturnal NE
excretion was noted, which was reduced only if whole night oxygenation was normalized during oxygen therapy.
Key words: chronic obstructive pulmonary disease; hypoxaemia; stress; thyroid stimulating hormone; thyroxin;
norepinephrine; epinephrine; testosterone; sex-hormone binding globulin; follicle stimulating hormone.
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There is an apparent clinical resemblance between a hyper-
thyroid state and advanced chronic obstructive pulmonary
disease (COPD). In both conditions tachycardia, weight
reduction and loss of muscle mass may be found. In COPD
complicated by hypoxaemia these traits may be aggravated,Received 10 April 2000 and accepted in revised form 17 August
2000.
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0954-6111/00/121221+08 $35?00/0since chronic or intermittent hypoxaemia may trigger a
hypermetabolic state causing depletion of fat-free mass (1).
Hyperthyroidism increases work of breathing by elevating
the chemosensitivity and respiratory drive (2). Early
detection of thyroid disturbances may therefore be clini-
cally important in COPD.
In studies of animals as well as of healthy human subjects
a close anatomical and functional relationship has been
found between catecholamine secretion and thyroid hor-
mone secretion, whereas an inverse relationship has been
noted in primary thyroid abberrations (3–5). Chronic
nocturnal hypoxaemia such as in obstructive sleep apnoea
(OSA) is associated with increased catecholamine secretion,
which is reduced by long-term continuous positive airway# 2000 HARCOURT PUBLISHERS LTD
1222 T. BRATEL ET AL.pressure (CPAP) treatment (6–8). We have recently shown
that such a reduction in nocturnal urinary NE excretion in
OSA patients is associated with an altered thyrostat (8).
However, to our knowledge, the effects of elevated
catecholamine secretion induced by chronic hypoxaemia
due to COPD on thyroid secretion have not been studied.
Most alterations of the thyrostat are easily demonstrated
by measurement of thyroid stimulating hormone (TSH)
employing ultrasensitive methods (9), but primary distur-
bances of the hypothalamic–pituitary–thyroid axis at the
pituitary level are best revealed by thyroid releasing
hormone (TRH) challenge (10). As well as the pituitary–
thyroid axis, other parts of the frontal pituitary lobe may be
affected by chronic hypoxaemia. Reduced as well as
increased serum gonadotropins are reported in COPD
complicated by hypoxaemia (11,12).
Chronic hypoxaemia in stable COPD is associated with a
very slow increase in pulmonary pressures and deteriora-
tion of blood gases (13,14). Only minor acute effects on
pulmonary hypertension were induced by oxygen supple-
ment in the NOTT study and these effects could not predict
the effects of 6 months of long-term oxygen therapy
(LTOT) (15). In the present study, the hormonal impact
of chronic hypoxaemia in COPD was evaluated before
treatment and the possible hormonal effects of oxygen
therapy were therefore evaluated after on average 8 months
of LTOT and the patients were used as their own controls.
Patients and methods
SUBJECTS
The patient group comprised 12 male COPD patients aged
69?5 (30–79) years and with severe airway obstruction and
daytime hypoxaemia (PaO257?3 kPa) or with daytime
PaO2 of 7?3–8?7 kPa, but with substantial nocturnal
hypoxaemia associated with oedema of the lower extremi-
ties. All patients were ex-smokers and they were clinically
stable and none had had an exacerbation of their
respiratory disease within the 3 weeks prior to the study.
LTOT was thus given according to the guidelines of the
European Society of Pneumology (16). The study was
approved by the ethical committee of Huddinge University
Hospital and all patients gave their informed consent.
Chest radiographs and electrocardiograms showed that
no patient suffered from uncontrolled left heart failure.
None of the patients had a history of heavy snoring or
witnessed apnoeas. One patient had well controlled insulin-
dependent diabetes mellitus. Two patients were treated
continuously with oral corticosteroids (10mg of predniso-
lone) and one by repeated courses. No additional hormonal
treatment was given to the patients. Ten patients were given
theophylline preparations and seven were receiving oral b2-
agonists. All patients used inhaled b2-agonists and inhaled
steroids. Ten patients were treated with furosemide
(40–160mg) and four with spironolactone (50–100mg).
Medication was kept essentially unchanged during the
study period. Twenty age-matched [68 (29–80) years]
healthy males served as controls regarding serum gonado-tropin and testosterone levels. All other hormonal variables
were compared to the reference limits of our laboratory.
PHYSIOLOGICAL AND LABORATORY
INVESTIGATIONS
The patients were admitted to the pulmonary department
for assessment of their need for LTOT. Forced expiratory
volumes were measured by dynamic spirometry (Vitalo-
graph1, Buckingham, U.K.) in the afternoon about 30min
after b2-stimulation. The best of three trials of forced
expiratory volume in 1 sec (FEV1) was used for statistical
analysis and forced vital capacity (FVC) was taken from
the same measurement. Urine for catecholamine assays was
collected (from about 22.00 hours in the evening until 07.00
hours the following morning) simultanously with a finger
pulse oximetry (Radiometer A/S, Copenhagen, Denmark).
The mean arterial oxygen saturation for the whole night
(MSaO2) was calculated and the cumulative percentage of
the nocturnal recording time with a SaO2 level5 90% and
5 85% (%t SaO25 90% and %t5 85%, respectively) was
estimated. All oximetry tracings were scrutinized manually
by the same observer (TB) without knowledge of the
hormonal results. Arterial blood gases (ABL 520, Radio-
meter A/S) were drawn with the patient seated and resting
at around 08.00 hours in the morning following the
nocturnal pulse oximetry. Venous blood for hormone
analyses was drawn with the patient supine and resting
between 07.00 – 08.00 hoursthe same morning.
A TRH stimulation test was then performed after
breakfast by use of an i.v. injection of 200mg of TRH
(Thyrefact1, Hoechst A.G., Frankfurt, Germany). Venous
blood samples were drawn immediately before and 20 and
60min after the injection of TRH for analysis of thyroid
stimulating hormone (TSH), prolactin (PRL) and growth
hormone (GH). A normal TRH response in males above 40
years of age is characterized by an increase in TSH and
PRL levels by 100% and an increase in GH levels by
100% (10,17). The response to TRH stimulation is
expressed as the D-value (i.e. the maximum value following
TRH injection minus the basal level prior to injection).
The oxygen treatment was titrated over the following
days, aiming to reach a daytime PaO2 level of at least
8?0 kPa and SaO24 90% during a whole night without
causing the morning PaCO2 to be raised above 8?0 kPa.
Patients were treated for an average of 16 (range 14–
18) h day71 by a mean oxygen dose of 1?8+ 0?8 lmin71.
After a mean treatment time with LTOT of 8?25+ 2?34
months all measurements were repeated. The nocturnal
urinary catecholamine collection and concurrent pulse
oximetry as well as blood gas sampling were this time
performed during ongoing oxygen therapy. In addition to
the whole-night oximetry, the breathing pattern of the
patient was assessed using a static-charge sensitive bed
(SCSB) (Bio-matt, Biorec, OY, Finland) (18). Adherence to
the prescribed oxygen treatment was assessed by open
questionning and by examination of the counters of the
oxygen compressors by medical technicians.
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Serum concentrations of prolactin (PRL), TSH, triio-
dothyronine (T3), free thyroxine (fT4) and growth hormone
(GH) were measured by time-resolved fluorescence immu-
noassay using commercial kits from Wallac OY, Turku,
Finland (Delfia1, Autodelfia1). Serum concentrations of
luteinizing hormone (LH), follicle stimulating hormone
(FSH), testosterone (T) and sex-hormone binding globulin
(SHBG) were determined by radioimmunological or
immunoradiometric methods using commercial kits from
Diagnostic Products Corp., Los Angeles, CA, U.S.A. (LH,
FSH, T) and Orion OY, Turku, Finland (SHBG). NE and
E in plasma and urine were determined using a modified
high pressure liquid chromatography technique (19,20).
Practical detection limits and within and between assay
coeffecients of variation were: for PRL 0?04mg l71, 4% and
5%; for TSH 0?4mU l71, 5?0% and 7?2%; for T3,
0?3 nmol l71, 4?1% and 4?1%; for fT4 2 pmol l
71, 9?8%
and 7?0%; for GH 0?01 mg l71, 2?5% and 4?9%; for LH
1?2U l71, 7% and 10%; for FSH 1?2U l71, 7% and 11%;
for T 0?1 nmol l71, 6% and 10% and for SHBG 6nmol l71,
5% and 11%. Total coecients of variation for plasma
catecholamines were 18% at about 2?5 nmol l71 and for
urinary catecholamines 5% at the upper reference level (see
Table 2).
Apparent concentrations of free testosterone (fT) were
calculated from values for total T, SHBG and a fixed
albumin concentration of 42 g l71 by successive approx-
imation using a computer programme based upon an
equation system derived from the law of mass action (21).TABLE 1. Anthropometric and physiological data presented as
Blood gases and oxymetry measurements after LTOT were per
Befor
BMI, (kgm72) 25?0
FEV1 of % predicted 34?3
FVC of % predicted 56?5
FEV1FVC(%) 45?5
Pulse (bpm) 78?6
Systemic BP, (mm Hg) 119?2
Diastolic BP, (mm Hg) 71?7
P aO2 (kPa) 7?39
P aCO2, (kPa) 5?65
MSaO2 (%) 86?6
Nadir SaO2 (%) 76?1(6
%t SaO25 90% 93?3 (
%t SaO2585% 8?2 (
Hb, g l71 154?5
Abbreviations: BMI: body mass index; FEV1: forced expiratory
arterial oxygen saturation during the whole night; Nadir Sa
SaO25 90% or 5 85%: cumulative time of the nocturnal re
Significant differences induced by treatment are denoted by *PSTATISTICAL ANALYSIS
Normally distributed values were expressed as arithmetric
mean + SD, otherwise as median and range. Results before
and after LTOT were compared by paired Student’s t-test if
normally distributed, otherwise by Wilcoxon’s signed-rank
test. Differences between subgroups were compared using
unpaired Student’s t-test or Mann–Whitney U-test and
correlations between variables were assessed by linear
regression or by Spearman’s rank test according to
distribution. The contribution of several parameters to
the variability of a dependent variable was evaluated by




Anthropometric and physiological data are given in
Table 1. All patients suffered from severe irreversible
airway obstruction with a FEV1 in percentage predicted
(%P) of 34?3+ 13?1% (range: 18–65%) and all had FEV1/
FVC below 70%. Five patients had pre-treatment daytime
PaO2 below 7?3 kPa, five had PaO2 values ranging between
7?6 and 7?8 kPa and in two cases PaO2 ranged between 8?3
and 8?7 kPa. Two patients had PaCO2 above 6?0 kPa and
the remaining patients had normal values (Table 1). All but
one of the patients had mean nocturnal SaO2 (MSaO2)
below 90% and no patient had nadir nocturnal SaO2 abovemean+ SD or median and range according to distribution.
formed during ongoing oxygen therapy
e LTOT After LTOT
+ 3?8 24?9+ 4?8
+ 13?1 33?3+ 13?9
(39–92) 42?0 (35–108)
(23–75) 45?5 (22–76)
+ 14?4 76?7+ 12?6
+ 13?6 122?0+ 9?8*
+ 7?2 76?0+ 11?5
+ 0?78 9?03+ 0?76**
+ 1?11 5?34+ 1?00





volume in 1 sec; FVC: forced vital capacity; MSaO2: mean
O2: the lowest SaO2 during the nocturnal recording;%t -
cording spent below a SaO2 of 90% or 85% respectively.
50?05 and **P5 0?01.
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%tSaO25 90% exceeding 80% of the night and both had
signs of right heart failure. A quarter of the patients spent
at least 25% of their time in bed with%tSaO25 85%. Mean
BMI was normal, five subjects had a body mass index
(BMI) in the lower range of normal i.e. below 23 kgm72.
Pulse rate was above 75 beats per min in half of the
patients, yet systemic blood pressure was normal or low in
all subjects.
Endocrine data are given in Table 2. Median P-NE was
above and 9-h nocturnal urinary (U) NE was slightly below
the upper limit of normal. Values for thyroid hormones,
basal levels and increments following TRH challenge test
for TSH, PRL and GH were within the normal ranges of
our laboratory. Patients and controls did not differ with
respect to LH, FSH, total and free testosterone and SHBG.
Group comparisons between the three patients treated
with oral corticosteroids and the nine patients treated with
only inhaled corticosteroids showed no significant differ-
ence regarding any hormonal parameter.
AFTER LTOT
Eight months of LTOT significantly increased mean values
of PaO2, MSaO2 and nadir SaO2, and significantly reduced
percent t SaO25 90% and percent t SaO25 85% (Table 1).
All of these variables were measured during ongoing
oxygen therapy. PaO2 was raised to at least 8?0 kPa in all
subjects and MSaO2 was elevated to above 90% in all but
one patient. In one patient MSaO2 could not be determined
before treatment. Following LTOT there was a slight but
significant increase in systolic blood pressure but no
significant change in lung function, although there was aTABLE 2. Endocrine variables before and after LTOT. Data are
distribution. For abbreviations see text
Controls






S-PRL (mg l71) 511*
DPRL (mg l71)
S-GH (mg l71) 55?60*
DGH (mg l71)
S-T (nmol l71) 17?9 + 6?9{
S-SHBG (nmol l71) 43?4 + 14?4{
fT (pmol l71) 372?5 + 143?3{
S-LH (U l71) 7?0 (3?0 – 16?0){
S-FSH (U l71) 6?0 (1?0 –28?0){
P-NE (nmol l71) 0?7–2?3*
U-NE (nmol l71) 5178*
P-E (nmol l71) 50?70
U-E (nmol l71) 0 –30*
*Reference levels of our laboratory. {Healthy controls.
Regarding reference levels for D values— see text.trend towards reduced FVC (P=0?07) (Table 1). In none of
the cases did SCSB measurements reveal a breathing
pattern compatible with OSA [i.e. five or more apnoeas
per hour, periodic breathing  20% of time in bed (18)]. No
significant endocrine changes occurred following treatment
in the entire patient group (Table 2).
The oxygen treatment increased MSaO2 by at least 7%
points in six patients (good responders) and by less than
7% points in five patients (poor responders). Data for the
two subgroups are given in Table 3. Compared to the poor
responders, the good responders had significantly lower
MSaO2 before treatment and a tendency to higher FEV1
%P (40.5+ 13?2% vs. 25?8+ 10?0%, P=0?07). The good
responders had significantly lower FSH and higher basal
TSH and DTSH values than the poor responders before and
after treatment. Serum FSH before and after treatment and
serum LH after treatment were significantly lower in the
good responders than in the controls. Prior to treatment the
good responders had significantly higher U-NE values than
the poor responders. After treatment U-NE, U-E and
serum fT4 levels decreased (P5 0?05 for all) within the good
responder subgroup. These parameters became significantly
lower and MSaO2 tended to become higher in the good
responder subgroup compared to the poor responders. In
the poor responders urinary catecholamines tended to
increase after LTOT. No significant difference with regard
to medication or oxygen dosage was noted between the two
subgroups.
CORRELATIONS
Reduced pretreatment FEV1%P was accompanied by
reduced basal and DTSH both before and after LTOTpresented as mean+ SD or median and range according to
Before LTOT After LTOT
1?2 (0?4 – 4?0) 1?0 (0?3 –5?5)
2?04 + 0?44 1?91 + 0?28
18?0 (11–22) 15?0 (10 –23) ?
5?0 (1?0–16?8) 5?0 (1?0–15?4)
4?2 (2?0–10?0) 6?0 (3?0 –13?0)
16?6 + 10?0 18?1 + 8?5
0?20 (0?04 –1?1) 0?40 (0?04 – 0?90)
0?45 (70?3–3?95) 0?40 (70?30–2?2)
14?3 + 6?9 15?6 + 6?5
38?0 + 22?9 39?7 + 25?3
304?3 + 111?1 334?8 + 117?7
7?8 (0?9 – 22?0) 4?4 (0?9 – 20?9)
6?5 (2?0 – 22) 4?0 (2?0 – 17)
3?2 (2?0 – 6?8) 3?9 (1?6 – 8?2)
160?5 (72 – 271) 144?0 (124 – 422)
0?10 (0?06 – 0?40) 0?10 (0?10 – 0?50)
7?50 (4?0 –19?0) 7?00 (4?0 –23?0)
TABLE 3. Significant differences between patients with an increase in nocturnal mean arterial oxygen saturation (MSaO2) of
57% points (poor responders) vs. of 7% points (good responders) following 8 months of oxygen treatment
DMSaO25 7 % DMSaO2 7%
Before LTOT
MSaO2(%) 89?2+ 2?5 84?5+ 2?4*
FSH (U l71) 9?0 (5?0–22?0) 3?1 (2?0–4?0)**
TSH (mU l71) 0?5 (0?4–1?3) 1?5 (1?0–4?0)*
DTSH (mU l71) 1?4 (1?0–5?9) 8?0 (4?3–16?8)*
fT4 (pmol l71) 17?5 (17–18) 19?0 (11–22)
U-NE (nmol71) 136?0 (72–208) 195?5 (150–271)*
U-E (nmol71) 7?0 (4–10) 8?5 (6–19)
After LTOT
MSaO2(%) 92?0+3?2 94?9+1?0(a)
fT4 (pmol71) 17?0 (15–23) 13?0 (10–17)*
U-NE (nmol71) 191?5 (144–422) 135?5 (124–175)*
U-E (nmol71) 15?5 (9–23) 6?0 (4–13)*
(a)P=0?06, *P50?05, **P50?01, regarding differences between subgroups.
For details of other abbreviations see Table 1 and text.
EFFECTS OF LONG-TERM OXYGEN TREATMENT FOR COPD 1225[Fig. 1 (a)]. Pre-treatment values of MSaO2 correlated
negatively to basal and DTSH before and after treatment
[Fig. 1 (b) and Table 4]. The amount of nocturnal time
spent with a SaO25 85% before treatment correlated
positively to pre-treatment U-NE levels as well as to basal
and DTSH before and after treatment (Table 4). Four out
of five patients with pre-treatment nocturnal U-NE above
the upper normal limit (i.e. 4178 nmol l71) spent more
than 10% of the night with a SaO2 below 85%, whereas all
but one of the subjects with nocturnal U-NE within normal
limits spent less than 2% of the night with a SaO25 85%
(Fig. 2).
Stepwise regression analysis comparing the influence
before treatment of age, PaO2, MSaO2, %tSaO25 85%
and FEV1%P on DTSH revealed that FEV1%P remained
the most significant variable, explaining 86% of the
variability (r2=0?86) regarding DTSH, only
%tSaO25 85% could further significantly contribute to
the regression model (increasing r2 to 0?95).
Plasma NE and serum fT4 were positively correlated
before treatment (r=0?80, P5 0?05). Serum total testoster-
one and SHBG were positively correlated in the patients
before and after LTOT (r=0?75 and r=0?79, P5 0?01 for
both) as well as in the controls (r=0?49, P50?05).
Discussion
Our twelve patients differed considerably regarding age,
degree of airway obstruction and hypoxaemia. Age may
influence the secretion of gonadotropins or thyroid
hormones (22,23). However, in our cohort, the effect of
age did not over-ride other physiological factors such as
oxygenation or lung function. The plasma NE levels were
about three times higher in our study of resting elderly ex-smokers compared to those of elderly, healthy, active
smokers (24). The elevated P-NE levels in our patients were
thus, probably, mainly due to the impact of disease and not
to previous smoking. Three of our patients were subjected
to long-term oral corticosteroid treatment. Systemic corti-
costeroids may reduce testosterone levels (25) as well as
exhibiting possible other hormonal effects. However, no
significant difference regarding levels of sex hormones or
other hormones were noted when these patients were
compared with the nine patients without oral corticosteroid
treatment.
Acute exposure (up to 4 h) of healthy subjects to severe
hypoxia is reported to result in increased E- as well as NE-
secretion, whereas chronic severe hypoxia (about 3 weeks)
was followed by further increments in NE but by normal-
ized E-secretion (26). Despite hypoxaemia the cellular
machinery strives to maintain normal production of high
energy phosphate compounds by increasing substrate
turnover for these compounds. In an acute state this is
achieved by glycogenolysis, which is mainly stimulated by E
(26). A long-term energy supply in chronic severe hypoxic
conditions is maintained by NE stimulated lipolysis (27). In
accordance with these findings, the pre-treatment nocturnal
levels of NE were higher than normal in our good
responder subgroup who, in most cases, had severe chronic
hypoxaemia (MSaO25 85%). The only significant correla-
tion between hypoxaemia and catecholamines was noted
between an index of severe nocturnal hypoxaemia (% time
SaO25 85%) and nocturnal urinary NE excretion. Clear
inverse correlations have been found between severe
hypoxaemia and daytime plasma NE levels in COPD (28)
but no changes in P-NE levels followed after inhalation of
pure oxygen for 30min (28) or after 8 months of LTOT as
in the present study. However, nocturnal NE excretion was
reduced in our good responder subgroup who, after LTOT,
FIG. 1. (a) Association between stimulated TSH (DTSH) before LTOT and pre-treatment FEV1%P (rs=0?88; P50?01). 1 (b)
Association between pre-treatment-stimulated TSH (DTSH) and mean nocturnal SaO2 (MSaO2) before LTOT (rs=70?76;
P50?05).
FIG. 2. Association between pre-treatment percentage of
time in bed spent with SaO2585% (% time SaO2585%)
and pre-treament nocturnal urinary norepinephrine
excretion (U-NE) (rs=70?67; P50?05).
TABLE 4. Significant correlations (Spearman rank) between
indices of pre-treatment nocturnal hypoxaemia and hor-
monal levels
MSaO2(rs) % Time SaO25 85% (rs)
S-TSH I 70.69* 0.78*
S-TSH II 70.69* 0.98**
DTSH I 70.76* 0.78*
DTSH II 70.72* 0.90**
U-NE I 70.54 NS 0.67*
*MSaO2: mean nocturnal arterial oxygen saturation;%
time SaO2 585%: cumulative nocturnal time spent with
SaO2 below 85%; S: serum; U-NE: urinary norepinephrine;
I: before LTOT; II: after 8 months of LTOT. For other
details of abbreviations see Table 1 and text.
*P50?05; **P50?01; NS: not significant.
1226 T. BRATEL ET AL.showed a substantial improvement and normalization in
mean nocturnal SaO2(MSaO2493%) (29) (Table 1). NE-
secreting neurons may thus react only to severe hypoxaemia
(SaO2585%) and reductions in nocturnal catecholamine
excretion may be induced only following substantial long-
term improvements in sleep-related oxygenation (7,8).
Despite oxygen therapy in hypoxic COPD patients for
several months, NE levels are persistently elevated, which
has been attributed to the strain caused by the severe airway
obstruction in advanced COPD (30). In our poor responder
subgroup who tended to have to the most severe airway
obstruction, several months of LTOT was followed by a
substantial increase in nocturnal catecholamine excretion,but only by a small improvement in nocturnal oxygenation.
The impact of improved oxygenation on catecholamine
excretion in this subgroup may have been outweighed by
the continuously strenuous effects of chronic severe airway
obstruction.
In accordance with previous studies of chronic hypox-
aemia (8,11,12) the hypothalamic–pituitary–thyroid axis
functioned normally in the present study. Nevertheless,
EFFECTS OF LONG-TERM OXYGEN TREATMENT FOR COPD 1227basal and stimulated TSH levels were reduced in our
patients with severe airway obstruction and remained
unaltered despite improved oxygenation following LTOT.
Subnormal basal and stimulated TSH levels are reported in
other critical non-thyroidal diseases and are considered to
predict a poor prognosis (31,32). Thus, severe irreversible
airway obstruction seems to have profound systemic effects
comparable with those of other fatal non-thyroidal
diseases.
Improved oxygenation had insignificant effects on the
thyrostat at the pituitary level in the present study.
However, a small reduction in free thyroxin was noted in
our good responder subgroup, in which a reduced
nocturnal NE excretion was also noted. In vitro studies
show that reduced NE excretion is accompanied by reduced
deiodination of T4 to T3 leading to increased T4 levels (5).
However, high altitude studies in healthy subjects imply
that hypoxaemic stress decreases the pituitary or peripheral
conversion rate of fT4 to fT3 (33). Relief of the hypoxaemic
stress following LTOT in our good responder subgroup
could have increased this conversion rate.
While low circulating concentrations of gonadotrophins
in COPD patients with stable hypoxaemia or with acute
exacerbations have been reported (11,34), quite normal
values were found in our study group as a whole. However,
our good responder subgroup with severe pre-treatment
nocturnal hypoxaemia had subnormal FSH levels. Con-
trary to previous findings in stable hypoxaemic COPD
patients (35), we found neither gonadotropin levels nor free
and total testosterone to be significantly affected by LTOT.
Thus, our study suggests that chronic hypoxaemia is not of
major importance for determining gonadotropin levels in
COPD. Furthermore, serum total testosterone and SHBG
correlated positively in the patients before and after
treatment as well as in controls, which demonstrates an
intact hypothalamic–pituitary–gonadal axis in our patients.
This positive correlation does not reflect an effect of
testosterone binding to SHBG on androgen metabolism,
but rather the attempt to maintain a constant androgenic/
anabolic activity in a healthy organism with altered SHBG
levels due to for example nutritional changes (36,37).
In conclusion, patients with chronic hypoxaemia second-
ary to COPD exhibit elevated plasma NE levels but
otherwise normal endocrine values, including a normal
hypothalamic–pituitary–testicular axis as judged from the
positive associations between testosterone and SHBG. The
severity of airway obstruction is associated with reduced
basal and stimulated TSH. The endocrine function is not
significantly changed following LTOT except for a sub-
group with severe nocturnal hypoxaemia, where elevated
nocturnal NE excretion was noted, which was reduced only
if whole night oxygenation was normalized during oxygen
therapy.
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